Drug discovery and development have evolved drastically in the recent past and continue to trend with emerging advancements. Innovative and sophisticated approaches are being incorporated with novel modalities emerging continuously through multifaceted approaches.
Researchers and pharmaceutical giants are working extensively towards devising drug discovery approaches to establish simplified processes. This accelerates the process of finding a potential cure for diseases like cancers, genetic disorders, and rare diseases. For instance, Evotec has signed a multi-year collaboration with Takeda by which Evotec will improve its technology platform to establish at least five drug discovery programs in core therapeutic areas like oncology, neuroscience, gastroenterology, and rare diseases.
Chemical or biological molecules are tested for a specific therapeutic outcome using High-throughput screening (HTS) with regard to a specific biological target. Researchers are working towards the automation of organoid targets to be used for robust drug discovery processes using HTS. For instance, in September 2022, Molecular Devices entered into a collaboration with HeartBeat.bio AG, for automation and scaling of cardiac organoids for utility in the high-throughput screening process. This effectively targets the disease physiology along with as the assessment of cardiac toxicity using 3D cell cultures.
Technologies such as machine learning (ML) and Artificial Intelligence (AI) are increasingly used for the acceleration of laboratory-based drug discovery experiments and are positively impacting the growth of the market. For instance, in September 2022, CytoReason declared the extension of its collaboration with Pfizer to effectively utilize CytoReason’s artificial intelligence technology for drug development with Pfizer’s investment of USD 20 million.
Emergence of AI is revolutionary to gain scientific insights, establishing biomarkers, and development of models that predict an individual’s risk of developing various disease conditions. For instance, in September 2022, Novo Nordisk signed an agreement with Microsoft for the acceleration of its drug discovery and development process. The collaboration is intended to integrate Microsoft’s computational expertise with Novo Nordisk’s drug discovery capabilities.
Small-molecule drugs affect molecular pathways by focusing on specific proteins. Small molecules are either developed by rational drug design strategies or can be isolated from natural resources. Numerous potential small molecule compounds are discovered by pharmaceutical giants by their collaborative efforts. For instance, in October 2022, Eli Lilly and Schrödinger collaborated for the development of novel small molecule compounds. Schrödinger will evaluate and synthesize compounds per year, which will be developed by Lilly.
The demand for novel cancer therapeutics is on the rise in the U.S. due to the rising incidence of cancer cases. Novel therapeutic elements are discovered with consistent and collaborative research efforts to commercialize innovative, high-impact, and cost-effective therapeutics for various types of cancers. For instance, in July 2022, Aurigene Discovery Technologies entered into a collaboration with U.S. based EQRx to integrate Aurigene's small molecules interface with EQRx's business model to develop novel therapeutic candidates for immune-inflammatory diseases and oncology.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Drug Discovery And Development Laboratory Services Market
5.1. COVID-19 Landscape: Drug Discovery And Development Laboratory Services Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Drug Discovery And Development Laboratory Services Market, By Drug Type
8.1. Drug Discovery And Development Laboratory Services Market, by Drug Type, 2023-2032
8.1.1 Small Molecule
8.1.1.1. Market Revenue and Forecast (2019-2032)
8.1.2. Large Molecule
8.1.2.1. Market Revenue and Forecast (2019-2032)
Chapter 9. Global Drug Discovery And Development Laboratory Services Market, By Technology
9.1. Drug Discovery And Development Laboratory Services Market, by Technology, 2023-2032
9.1.1. High Throughput Screening
9.1.1.1. Market Revenue and Forecast (2019-2032)
9.1.2. Pharmacogenomics
9.1.2.1. Market Revenue and Forecast (2019-2032)
9.1.3. Combinatorial Chemistry
9.1.3.1. Market Revenue and Forecast (2019-2032)
9.1.4. Nanotechnology
9.1.4.1. Market Revenue and Forecast (2019-2032)
9.1.5. Other Technologies
9.1.5.1. Market Revenue and Forecast (2019-2032)
Chapter 10. Global Drug Discovery And Development Laboratory Services Market, By End Use
10.1. Drug Discovery And Development Laboratory Services Market, by End Use, 2023-2032
10.1.1. Pharmaceutical Companies
10.1.1.1. Market Revenue and Forecast (2019-2032)
10.1.2. Contract Research organizations (CROs)
10.1.2.1. Market Revenue and Forecast (2019-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2019-2032)
Chapter 11. Global Drug Discovery And Development Laboratory Services Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.3. Market Revenue and Forecast, by End Use (2019-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.1.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.1.5.3. Market Revenue and Forecast, by End Use (2019-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.3. Market Revenue and Forecast, by End Use (2019-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.5.3. Market Revenue and Forecast, by End Use (2019-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.6.3. Market Revenue and Forecast, by End Use (2019-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.2.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.2.7.3. Market Revenue and Forecast, by End Use (2019-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.3. Market Revenue and Forecast, by End Use (2019-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.5.3. Market Revenue and Forecast, by End Use (2019-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.6.3. Market Revenue and Forecast, by End Use (2019-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.3.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.3.7.3. Market Revenue and Forecast, by End Use (2019-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.5.3. Market Revenue and Forecast, by End Use (2019-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.6.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.6.3. Market Revenue and Forecast, by End Use (2019-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.4.7.2. Market Revenue and Forecast, by Technology (2019-2032)
11.4.7.3. Market Revenue and Forecast, by End Use (2019-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.3. Market Revenue and Forecast, by End Use (2019-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.4.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.4.3. Market Revenue and Forecast, by End Use (2019-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Type (2019-2032)
11.5.5.2. Market Revenue and Forecast, by Technology (2019-2032)
11.5.5.3. Market Revenue and Forecast, by End Use (2019-2032)
Chapter 12. Company Profiles
12.1. F Hoffmann-La Roche AG
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Agilent Technologies Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly and Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Thermo Fisher Scientific Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. AstraZeneca
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Laboratory Corporation of America Holdings
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Merck & Co. Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Abbott Laboratories Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Bayer AG
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bayer AG
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms